title: Update on first-line treatment of advanced ovarian carcinoma.
abstract: Despite the high response rate to first-line treatment of advanced ovarian cancer, the vast majority of patients relapse. Maximal debulking surgery and chemotherapy with a platinum doublet have remained the standard of care for many years and new approaches are imperative. Recent clinical trials have given grounds for hope. Neoadjuvant chemotherapy, intraperitoneal delivery, and dose-dense strategies have all shown promising results, as has the targeting of angiogenesis. A greater understanding of the molecular landscape of ovarian cancer is helping to identify new treatment options. In this review, we will highlight the key trials and recent progress in these areas.
authors: Department of Oncology, University College London Hospitals.
authors: Z
authors: Z
authors: Kemp
authors: Ja
authors: J
authors: Ledermann
keywords: angiogenesis; dose-dense; first-line therapy; intraperitoneal; neoadjuvant; ovarian cancer
references: Int J Gynecol Cancer. 2010 Aug;20(6):945-52
references: 20683400
references: BMJ. 2011 Jan 04;344:d8009
references: 22217630
references: J Clin Oncol. 2012 Feb 1;30(4):362-71
references: 22184370
references: N Engl J Med. 2011 Dec 29;365(26):2484-96
references: 22204725
references: J Clin Oncol. 1997 May;15(5):1938-44
references: 9164205
references: Lancet. 2002 Aug 17;360(9332):505-15
references: 12241653
references: J Clin Oncol. 2007 Nov 20;25(33):5180-6
references: 18024865
references: Pharmacogenet Genomics. 2010 May;20(5):327-37
references: 20393316
references: J Clin Oncol. 2012 Jun 10;30(17):2039-45
references: 22529265
references: J Clin Oncol. 2008 Apr 1;26(10):1642-9
references: 18375893
references: N Engl J Med. 1996 Jan 4;334(1):1-6
references: 7494563
references: Ann Surg Oncol. 2012 Mar;19(3):959-65
references: 21994038
references: Int J Gynecol Cancer. 2011 May;21(4):750-5
references: 21543936
references: J Clin Oncol. 2009 Mar 20;27(9):1419-25
references: 19224846
references: Gynecol Oncol. 2010 Oct;119(1):1-2
references: 20833283
references: JAMA. 2011 Jun 8;305(22):2295-303
references: 21642681
references: Int J Gynecol Cancer. 2012 May;22 Suppl 1:S18-20
references: 22543913
references: Cancer Res. 2000 Oct 1;60(19):5334-9
references: 11034066
references: J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91
references: 15547181
references: Gynecol Oncol. 2007 Apr;105(1):3-6
references: 17383545
references: Am J Clin Oncol. 1999 Dec;22(6):559-67
references: 10597739
references: N Engl J Med. 1995 Mar 9;332(10):629-34
references: 7845426
references: Gynecol Oncol. 2011 Jul;122(1):121-6
references: 21496891
references: Nature. 2011 Jun 29;474(7353):609-15
references: 21720365
references: JAMA. 2012 Jan 25;307(4):382-90
references: 22274685
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: J Clin Oncol. 2010 May 20;28(15):2505-11
references: 20406939
references: J Clin Oncol. 2004 Mar 15;22(6):1040-4
references: 15020606
references: J Clin Oncol. 2011 Oct 1;29(28):3798-804
references: 21859991
references: J Natl Cancer Inst. 2011 Feb 16;103(4):347-51
references: 21217084
references: Jpn J Clin Oncol. 2008 Jan;38(1):74-7
references: 18258715
references: Lancet. 2009 Oct 17;374(9698):1331-8
references: 19767092
references: Gynecol Oncol. 2010 Oct;119(1):32-7
references: 20584542
references: J Clin Oncol. 2000 Jan;18(1):106-15
references: 10623700
references: Cancer. 2007 Jan 15;109(2):221-7
references: 17154394
references: J Clin Oncol. 2011 Nov 1;29(31):4076-8
references: 21931032
references: J Natl Cancer Inst. 2000 May 3;92(9):699-708
references: 10793106
references: N Engl J Med. 2008 Apr 17;358(16):1663-71
references: 18420499
references: N Engl J Med. 2012 Apr 12;366(15):1382-92
references: 22452356
references: J Clin Oncol. 2001 Feb 15;19(4):1001-7
references: 11181662
references: N Engl J Med. 2011 Dec 29;365(26):2473-83
references: 22204724
references: Ann Oncol. 1999;10 Suppl 1:35-41
references: 10219451
references: J Clin Oncol. 2007 Nov 20;25(33):5165-71
references: 18024863
references: Lancet Oncol. 2013 Sep;14(10):1020-6
references: 23948349
references: Nat Rev Clin Oncol. 2010 Sep;7(9):508-19
references: 20700108
references: Gynecol Oncol. 2011 Sep;122(3):541-7
references: 21640372
references: Ann Oncol. 2005;16 Suppl 8:viii7-viii12
references: 16239238
references: N Engl J Med. 2006 Jan 5;354(1):34-43
references: 16394300
references: J Clin Oncol. 2008 Dec 1;26(34):5530-6
references: 18955455